Source Reference: Ben-David R, et al "Tumor characteristics associated with preoperatively detectable tumor-informed circulating tumor DNA in patients with renal masses suspicious for renal cell ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

Braun, MD, PhD, and Yu-Wei Chen, MD, MS ASCO Educational Book Share on Facebook ... The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades.

The findings underscore the critical role of tumor size reduction in improving survival outcomes for patients with advanced renal cell carcinoma ... Cancers Symposium (ASCO GU 2025), further ...

The ASCO GU 2023 abstracts on renal cell cancer represent continued evolution of treatment with immunotherapy, refinement of biomarkers, and updated imaging techniques. These abstracts are just a few ...

At the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2025 ... as a front-line therapy for intermediate or poor-risk advanced or metastatic renal cell carcinoma (RCC). RCC ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

AMARILLO, Texas (KAMR/KCIT) — Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences ...

Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma ... (CKD), investigators reported at ASCO’s 2025 Genitourinary Cancers ...